In recent years, scientists discovered that Hepcidin helps regulate the amount of iron in humans. Unbalanced iron level can lead to many common medical conditions including anemia and iron overload disease and it can occur in chronic kidney disease, inflammation, or diabetes mellitus.
“We at DRG International saw the need for an accurate and easy to use Hepcidin testing kit and have relished the great success that our research customers have seen using the product,” stated Dr. Cyril E. Geacintov, founder, president and CEO of DRG International. “This kit is an important step to meet the rapidly growing worldwide interest in Hepcidin testing and the applications of that testing in the health and wellness community.”
The DRG Hepcidin 25 (bioactive) ELISA Kit is available worldwide, providing a simple, fast and accurate method to test Hepcidin levels. DRG currently holds 19 active US and International patents on this product. The measurement results of this kit offer more information to help treat medical issues including iron deficiency diseases, which are some of the most common diseases worldwide. The kit is for Research Use Only (RUO) in the United States and is also CE marked.
DRG International will be showcasing at the AACC in Booth 2431. Press inquiries are welcome, for more information; please contact Evergreen Partners (press agent for DRG International) at (908) 322-1100.
###
DRG International, Inc. founded in 1970, is a multinational specialty medical equipment and diagnostics manufacturer and distributor with successful operations in over 110 countries.DRG supplies an extensive line of immunodiagnostic products including fertility and pregnancy tests, endocrinology/diabetes, saliva hormone diagnostics, tumor markers, infectious diseases, immunology/hematology, thyroid function panels, cardiovascular assays as well as therapeutic and toxicology screening products. To obtain more information about the DRG group of companies and complete product line, please visit our website at: www.drg-international.com.